Pharmaids Pharmaceuticals (524572) Q3 25/26 earnings summary

Executive summary

• Unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025, were approved by the Board on February 12, 2026.

• Both standalone and consolidated results were reviewed by statutory auditors, with no material misstatements identified.

Financial highlights

• Standalone revenue from operations for the quarter was Rs. 83.28 lakhs, with a net loss of Rs. 310.98 lakhs.

• Consolidated revenue from operations for the quarter was Rs. 543.00 lakhs, with a net loss of Rs. 264.60 lakhs.

• For the nine months ended December 31, 2025, standalone revenue was Rs. 596.55 lakhs and consolidated revenue was Rs. 2,069.85 lakhs.

• Standalone EPS for the quarter was Rs. (0.88); consolidated EPS was Rs. (0.70).

Outlook and guidance

• The company continues to focus on its core segment of Contract Research and Manufacturing Services.